Semaglutide also improved 6MWD, resulted in a greater number of wins versus placebo for the composite hierarchical endpoint and reduced systemic inflammation assessed by CRP in each obesity class, with no heterogeneity of treatment benefits (Fig. 2). The gene discussed is CRP; the disease is obesity due to melanocortin 4 receptor deficiency.